Compare MGIC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIC | ANAB |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2002 | 2015 |
| Metric | MGIC | ANAB |
|---|---|---|
| Price | $17.38 | $56.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $18.00 | ★ $62.20 |
| AVG Volume (30 Days) | 41.1K | ★ 413.2K |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | N/A | ★ 15.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $91,280,000.00 |
| Revenue This Year | $12.87 | $135.51 |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $21.93 | ★ N/A |
| Revenue Growth | N/A | ★ 432.03 |
| 52 Week Low | $11.65 | $14.01 |
| 52 Week High | $28.00 | $57.74 |
| Indicator | MGIC | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 64.52 |
| Support Level | $15.14 | $43.67 |
| Resistance Level | $21.16 | $57.65 |
| Average True Range (ATR) | 0.94 | 3.46 |
| MACD | -0.43 | 0.19 |
| Stochastic Oscillator | 3.18 | 87.14 |
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).